Study of the anti-proliferative and anti-migratory response of HU-VEC endothelial cells to the treatment with Paclitaxel anti-cancer agent

Abstract

Cancer treatment is one of the important challenges for healthcare systems. Among the new chemotherapeutic agents, the Taxane family has been introduced as the most powerful agent that exhibits a wide range of activity. Unlike tumor cells, normal endothelial cells have high stability and low mutation rates. Therefore, targeting endothelial cells It can be more useful and effective than tumor cells. Despite the emergence of anti-angiogenic or proliferative effects of taxanes on endothelial cells, there are limited studies on how this effect is molecular. This study investigates the effect of paclitaxel on mir-152, mir-433 and mir-16 mRNAs and VEGF target gene. Methods: HUVEC cell line is cultured in RPMI1640 medium and MTT assay is performed on them with different concentrations of Paclitaxel. The cells were then treated with IC50 drug concentration and total RNA was extracted and after cDNA synthesis, using real-time PCR quantification of mRNA and miRNAs controlling the expression of proliferation-related genes (mir-16, mir-433 and mir 152 target gene (VEGF) were examined.

Results: Treatment of the cells with paclitaxel caused changes in the studied genes expression. The expression of mir-16, mir-433 significantly increased and the expression of VEGF and mir-152 decreased.